Clinical Pharmacokinetics of Phenytoin
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Phenytoin is a relatively insoluble weak acid, usually administered as the sodium salt. Bioavailability is dependent upon particle size and problems of generic inequivalence have therefore arisen, particularly in Scandinavia. The drug has a moderately large volume of distribution and is approximately 90% bound to plasma proteins. Clinically important displacement can be caused by bilirubin and several drugs, particularly sodium valproate, which is often combined with phenytoin. Displacement will lower the total serum concentration but will little affect the free drug concentration. The metabolism of phenytoin to the major metabolite, 5-(p-hydroxyphenyl)-5-(phenylhydantoin, is saturable, giving rise to a non linear dose-serum concentration relationship. Therefore, the dose range compatible with a therapeutic serum concentration is narrow within subjects, and monitoring serum concentrations is of particular value in dosage tailoring. In renal failure, the binding of phenytoin to plasma proteins is reduced and therefore a lower range of serum drug concentrations is compatible with therapeutic control. In liver disease, binding may also be impaired but delayed metabolism may occur in addition. During pregnancy the serum concentration may fall progressively as pregnancy advances, probably due to an increased rate of metabolism. Phenytoin readily crosses the placenta, and is metabolised rapidly by the neonate exposed in utero.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Phenytoin is the canonical example: its clearance is governed by capacity-limited (Michaelis–Menten) CYP2C9 and CYP2C19 metabolism such that small dose increases at therapeutic levels can produce disproportionately large rises in steady-state concentration [65].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [65]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 117 · Cited by 201
Metadata
- Authors
- Richens, A.
- Affiliations
- National Hospital for Neurology and Neurosurgery (GB)
- Corresponding author
- Richens, Alan
- Venue
- Clinical Pharmacokinetics
- Published
- 1979
- Volume
- 4
- Issue
- 3
- Pages
- 153-169
- ISSN
- 0312-5963 (ISSN-L)
- OpenAlex
- W2002387779
- Cited by
- 201
- References
- 117
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 7 · 2023: 2 · 2022: 2 · 2021: 7 · 2020: 5 · 2019: 7 · 2018: 3 · 2016: 2 · 2015: 5 · 2014: 6 · 2013: 4 · 2012: 1
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- phenytoin, bioavailability, volume of distribution, protein binding, drug displacement, bilirubin, valproic acid, saturable metabolism, nonlinear pharmacokinetics, therapeutic drug monitoring, renal failure, liver disease, pregnancy, placental transfer, neonatal metabolism
- MeSH terms
- Aged, Blood Proteins, Epilepsy, Female, Humans, Infant, Newborn, Kidney Diseases, Kinetics, Liver Diseases, Phenytoin, Protein Binding
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Pharmacokinetics of Phenytoin. https://app.cochat.ai/papers/10.2165/00003088-197904030-00001
- The paper
- Richens, A. (1979). Clinical Pharmacokinetics of Phenytoin. Clinical Pharmacokinetics. https://doi.org/10.2165/00003088-197904030-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.